Yes, the four indications are excluded- and given that it is what Neuren wants to target it should have zero effect re valuations. Also, if Neuren wanted to go after another indication, I don't think it would be retrospective ie Acadia would surely have to have had commenced planning/trials at least?
Ann: Q2 2023 quarterly activity and cash flow report, page-11
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.10 |
Change
-0.620(2.99%) |
Mkt cap ! $2.569B | |||
| Open | High | Low | Value | Volume |
| $20.41 | $20.45 | $19.92 | $5.947M | 296.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 999 | $20.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.19 | 10 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |